BioPorto

Share Issue/Capital Change • Sep 12, 2013

September 12, 2013 Announcement no. 34

Completion of rights issue and capital increase

On August 16, 2013 BioPorto A/S published a prospectus in connection with a rights issue of minimum 40,000,000 and maximum 70,724,526 new shares with pre-emptive subscription rights for existing shareholders of BioPorto A/S, cf. company announcement no. 30 of August 16, 2013. As announced in company announcement no. 33 of September 6, 2013, the rights issue was fully subscribed.

Completion of the rights issue

BioPorto A/S has now received the full subscription amount, and today the company has procured that the capital increase of in total nominally DKK 70,724,526 has been registered with the Danish Business Authority.

BioPorto A/S' gross proceeds from the rights issue amount to DKK 70,724,526 of which DKK 9,989,499 is paid by conversion of debt. The aggregate net proceeds amount to approximately DKK 65.4 million after deduction of costs for the completion of the rights issue.

Admission to trading and official listing

The new shares will as soon as possible be admitted to trading and official listing on NASDAQ OMX Copenhagen A/S under the ISIN code of the company's existing shares (ISIN DK0011048619), which is expected to take place on September 17, 2013.

Share capital after the rights issue

As a result of the rights issue, BioPorto A/S' share capital has been increased by nominally DKK 70,724,526. Accordingly, the total share capital of BioPorto A/S now amounts to DKK 117,874,210 divided into 117,874,210 shares of nominally DKK 1 each, equivalent to 117,874,210 votes. BioPorto A/S' articles of association have been updated accordingly and are available on the company's website.

Conversion of bridge financing and payment of convertible bonds

In connection with completion of the rights issue, the bridge financing with a principal amount of DKK 8,000,000 taken up by the company in June 2013, cf. company announcement no. 22 of June 13, 2013, has been converted into new shares in the company. Additionally, a total of DKK 1,989,499 of the gross proceeds from the rights issue has been paid in by debt pursuant to convertible bonds (ISIN DK0030263454) issued by BioPorto A/S on September 8, 2010.

Yours sincerely BioPorto A/S

For further information please contact:

Peter Mørch Eriksen, CEO Christina Thomsen, Investor relations Tel.: 45 29 00 00, e-mail investor@bioporto.com